The portfolio diet has four main components. “But when you pool the results of several trials, the risk reductions become clear and together they provide a really strong case for the cardiovascular benefits of the dietary portfolio.” “When you look at individual trials alone, data on these other risk factors can appear random,” says David Jenkins, a professor in the Departments of Nutritional Sciences and Medicine at U of T who holds a Canada Research Chair in Nutrition and Metabolism, and who developed the portfolio diet in the early 2000s. The journal Progress in Cardiovascular Diseases published the results today. The researchers conducted a meta-analysis that combined results from seven controlled trials involving more than 400 patients, and found that specific risk factors varied from about a 2 per cent reduction (for blood pressure) to a 32 per cent reduction (for inflammation). “This study allows for greater clarity and certainty about the effects of the diet and its health potential.” “We’ve known the portfolio diet lowers LDL cholesterol, but we didn’t have a clear picture of what else it could do,” says John Sievenpiper, an associate professor in the Department of Nutritional Sciences at U of T and a staff physician and scientist at St. In addition to reducing LDL (or ‘bad’) cholesterol by about 30 per cent when combined with a low-saturated fat diet - a level comparable to medications - the researchers found the diet limited other factors for an estimated 13 per cent reduction in the overall risk for coronary heart disease, which includes angina and heart attack. 2018‐03‐04 to 2018‐03‐07.University of Toronto researchers have found that the portfolio diet, a plant-based way of eating previously shown to lower cholesterol levels, reduces other risk factors for cardiovascular disease including blood pressure, triglycerides and inflammation. 25th Conference on Retroviruses and Opportunistic Infections, CROI 2018.Heart of England NHS Foundation Trust, United Kingdom.Cochrane Central Register of Controlled Trials (CENTRAL).
#Port folio diet full
Analysis assuming full compliance and preserving randomisation suggests a possible doubling of this estimated treatment effect. Conclusion: Dietetic advice to follow a Mediterranean diet containing nuts, plant stanols, soya protein, beans and oats produced a greater improvement in diet quality, blood pressure, and a 10% greater reduction in LDL‐cholesterol than standard guidelines to reduce saturated fat intake. As expected, the estimated treatment effect among compliers to MedDiet (LDL‐cholesterol ‐0.87mmol/l, 95%CI ‐1.79 to 0.05) and Portfolio foods (‐0.76mmol/l, 95%CI ‐1.54 to 0.01) appears larger than that for ITT analysis (‐0.38mmol/l, 95%CI ‐0.68 to ‐0.09). Body composition, arterial stiffness, gut function, and levels of physical activity were not significantly different between the groups. Individual adherence varied from 11 to 100% (mean 59☒1%). Intake of Mediterranean (olive oil, fish, legumes) and Portfolio foods (nuts, stanols) increased significantly in the Diet2 group (p<0.01). At 6 months, Diet2 participants (n=29) showed a significantly greater reduction in LDL‐cholesterol, total to HDL‐cholesterol ratio, systolic blood pressure (BP) and increase in Mediterranean Diet Score, than those in Diet1 (n=31), see table. Baseline characteristics were comparable between groups. Results: 60 eligible adults were randomized with mean age 42☗years, LDL‐cholesterol 3.9☐.6mmol/l, 50% female, 65% non‐smokers, 50% black African, 40% white European. Analysis was by intention to treat (ITT) and Complier Average Causal Effect. Betweengroup changes of CVR factors were assessed using ANCOVA, with adjustments for baseline values of the dependent variables. Measurements of CV risk factors, fasting blood lipids, food intake, body composition, and arterial stiffness were conducted at baseline, month 6 and month 12.
Randomization (1:1) compared the effect of dietary advice to reduce saturated fat (Diet1) versus MedDiet with additional cholesterol lowering foods e.g.
#Port folio diet trial
Methods: This pilot, parallel, randomized controlled trial (ISRCTN32090191) recruited adults with stable HIV infection on ART and LDL‐cholesterol >3mmol/l from 3 UK centres. This trial aims to examine the effect of dietary intervention on cardiovascular risk (CVR) in HIV dyslipidaemia.
Background: The risk of cardiovascular disease is increased in the HIV population, potentially due to the additional burdens of infection, inflammation and antiretroviral treatment (ART).
0 kommentar(er)
